Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRx

August 18, 2021

BOSTON & SAN FRANCISCO–(BUSINESS WIRE)– Pear Therapeutics, Inc. today announced formulary availability of its commercial products at OptumRx, Inc., the innovative pharmacy care services business of Optum, Inc. Pear’s commercial products include the Prescription Digital Therapeutics (PDTs) reSET® and reSET-O® for the treatment of substance use disorder and opioid used disorder, respectively, and Somryst® for the treatment of chronic insomnia.

Read the source article at Home – Neuro Central
2021-08-10 19:02:13

Share This Story!